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Summary 26 
 27 
New drugs against Trypanosoma brucei, the causative agent of Human African 28 
Trypanosomiasis, are urgently needed to replace the highly toxic and largely 29 
ineffective therapies currently used.  The trypanosome alternative oxidase (TAO) is an 30 
essential and unique mitochondrial protein in these parasites and is absent from 31 
mammalian mitochondria, making it an attractive drug target.  The structure and 32 
function of the protein are now well characterized, with several inhibitors reported in 33 
the literature which show potential as clinical drug candidates.  In this review we 34 
provide an update on the functional activity and structural aspects of TAO.  We then 35 
discuss TAO inhibitors reported to date, problems encountered with in vivo testing of 36 
these compounds, and discuss the future of TAO as a therapeutic target. 37 
 38 
Key Words: Trypanosome Alternative Oxidase, Drug Discovery, Chemotherapy, 39 
Human African Trypanosomiasis, Sleeping Sickness, Trypanosoma brucei 40 
 41 
 42 
 43 
 44 
 45 
 46 
  47 
 3 
THE TRYPANOSOME ALTERNATIVE OXIDASE: A POTENTIAL DRUG TARGET? 48 
  49 
INTRODUCTION  50 
Up to 70 million people in sub-Saharan Africa are at risk of contracting Human 51 
African Trypanosomiasis (HAT) (Simarro et al. 2012), also known as African 52 
Sleeping Sickness, caused by the kinetoplastid parasite Trypanosoma brucei.  Two 53 
subspecies of the parasite cause disease in humans; T. brucei gambiense in West 54 
Africa and T. brucei rhodesiense in East Africa, both of which are spread by the 55 
tsetse fly.    Both forms are fatal if untreated and are estimated to cause up to 20,000 56 
cases of HAT per year (World Health Organization 2013).  T. brucei evades the 57 
mammalian host immune system by changing their major surface coat proteins, 58 
known as variant surface glycoproteins (VSG), prior to each wave of host antibodies 59 
raised against the previous VSG type.  Due to this sophisticated immune evasion 60 
technique known as antigenic variation, a vaccine against the disease is unlikely in 61 
the near future. Drugs currently in clinical use are associated with severe adverse 62 
effects, difficult administration, and increasing concerns regarding drug resistance.  63 
Therefore, new drugs are urgently required (Lüscher et al. 2007).  The drugs 64 
indicated for treatment of the disease (Figure 1) depend upon the subspecies of 65 
parasite and stage of the disease.   66 
 67 
Early stage T. b. gambiense is treated with pentamidine, a diamidine hypothesized to 68 
act as a trypanocidal agent through several mechanisms, including disruption of the 69 
nucleus, kinetoplast and mitochondrial membrane potential (Baker et al. 2013).  Late 70 
stage T. b. gambiense is treated with a combinational therapy of nifurtimox and 71 
eflornithine.  Eflornithine is the only drug for HAT with a defined target, the ornithine 72 
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decarboxylase, but the drug has poor potency against T. brucei and combination 73 
therapy is required to prevent drug resistance acquired by loss of the drug uptake 74 
transporter  (Barrett & Croft 2012).  Suramin is recommended only for early stage T. 75 
b. rhodesiense due to its inability to penetrate the blood brain barrier.  Although the 76 
mechanism of uptake by the parasites is known, the trypanocidal mode of action still 77 
remains to be determined (Barrett & Croft 2012, Zoltner et al. 2016).  The arsenical-78 
based drug melarsoprol is recommended for late stage T. b. rhodesiense due to its 79 
ability to cross the blood brain barrier, however this property creates the often fatal 80 
adverse effect of encephalopathy in up to 10% of patients treated with the drug 81 
(Kuepfer et al. 2012).   82 
Differences in the biochemical processes between mammalian and trypanosomatid 83 
mitochondria make the mitochondrion an attractive drug target.  One main difference 84 
between T. brucei and mammalian mitochondrial respiration is the presence of the 85 
trypanosome alternative oxidase (TAO), an essential non-cytochrome terminal 86 
oxidase which has been extensively characterized as a drug target.  This review will 87 
summarize the structure and function of TAO and discuss the current progress 88 
towards the development of inhibitors against this protein.   89 
 90 
STRUCTURE AND FUNCTION OF THE TRYPANOSOME ALTERNATIVE 91 
OXIDASE 92 
Function 93 
In 1960, Grant and Sargent first described the glycerol-3-phosphate oxidase (GPO) 94 
system as a cyanide-insensitive, oxygen-dependent mechanism of respiration in 95 
Trypanosoma brucei rhodesiense (Grant & Sargent 1960).  The GPO system 96 
consists of two enzymes; a mitochondrial FAD+-dependent glycerol-3-phosphate 97 
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dehydrogenase (mG3PDH) and a terminal oxidase they termed the glycerol-3-98 
phosphate oxidase.  Clarkson et al (Clarkson et al. 1989) proved that ubiquinol links 99 
the dehydrogenase and oxidase of the GPO system by acting as an electron carrier, 100 
and proposed that glycerol-3-phosphate oxidase was similar to the plant alternative 101 
oxidase (AOX) and therefore should be renamed the trypanosome alternative 102 
oxidase (TAO). The GPO system is responsible for the cyanide-insensitive oxygen-103 
dependent respiration in bloodstream form T. brucei, where the GPO shuttle 104 
facilitates the reoxidation of NADH to NAD+ required for glycolysis.  As shown in 105 
Figure 2, the mG3PDH oxidizes glycerol-3-phosphate (Gly-3-P) to dihydroxyacetone 106 
phosphate (DHAP), during which four electrons are transferred to ubiquinol.   The 107 
electrons from ubiquinol are subsequently oxidized by TAO to convert dioxygen into 108 
water.  Alternative oxidases are found across a broad range of organisms, including 109 
plants, nematodes, algae, yeast and T. brucei, but, curiously, are not known to be 110 
present in the other human-infective trypanosomatids such as T. cruzi or Leishmania 111 
spp. 112 
TAO was first identified in Trypanosoma brucei by Chaudhuri et al (Chaudhuri et al. 113 
1995) using antibodies against the alternative oxidase from Sauromatum guttatum, 114 
which detected a 33 kDa protein in the parasite’s mitochondria.  This 33 kDa protein 115 
was subsequently purified from bloodstream form T. brucei mitochondria and 116 
confirmed to have ubiquinol oxidase activity.   Chaudhuri et al (Chaudhuri et al. 117 
1998) found that bloodstream form T. brucei express TAO 100-fold more than 118 
procyclic form, which is believed to be due to the ability of procyclic forms to express 119 
Complexes III and IV for ATP production via oxidative phosphorylation.  Using areas 120 
of high conservation in plant alternative oxidases, primers were designed to amplify 121 
TAO from T. brucei gDNA (Chaudhuri & Hill 1996).  This enabled the identification of 122 
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the single copy TAO gene (Tb927.10.7090) and subsequent cloning of TAO for 123 
recombinant expression in Escherichia coli (Chaudhuri & Hill 1996).  Recombinant 124 
TAO (rTAO) was subsequently used to determine the functional activity, kinetics and 125 
inhibitors of the enzyme.  Due to the endogenous ubiquinol oxidase activity of E. coli 126 
by the cytochrome bo and bd complexes, it was necessary to perform these 127 
investigations using hemA mutant E. coli, which are unable to synthesize the heme 128 
necessary for cytochrome assembly. The ability of rTAO to restore respiration in 129 
these cells showed the ability of TAO to function as a cyanide-insensitive terminal 130 
oxidase.  Research of rTAO by the Kita group established protocols for the 131 
overproduction, solubilization and purification of rTAO for use in kinetic, structural 132 
and inhibitor studies (Fukai et al. 1999; Fukai et al. 2003; Nihei et al. 2003; Yabu et 133 
al. 2003).  134 
TAO has been implicated in several other cellular activities, such as protection 135 
against reactive oxygen species and regulation of surface protein expression.  A role 136 
of AOX in photosynthetic plants is the rapid turnover of NADPH to protect the 137 
photosynthetic machinery from radicals.  It is possible that TAO has a related 138 
function in T. brucei, to protect the rapidly metabolizing cells from damaging radicals.  139 
The inhibition of TAO has been shown to induce oxidative damage to proteins and 140 
increase production of reactive oxygen species (Fang & Beattie 2003).  Similarly, 141 
inhibition of the electron transport chain and exposure to hydrogen peroxide causes 142 
an upregulation in the expression of TAO (Fang & Beattie 2003). This protection 143 
against oxidative damage may explain the ability of TAO to inhibit drug-induced 144 
programmed cell death-like phenomena in T. brucei (Tsuda et al. 2006).  Vassella et 145 
al (Vassella et al. 2004) reported the effects of TAO inhibition on the expression 146 
levels of the procyclin GPEET, a cell surface protein found in procyclic form T. 147 
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brucei.  In the presence of the TAO inhibitor salicylhydroxamic acid (SHAM), GPEET 148 
levels were heavily reduced, leading the authors to hypothesize that the level of 149 
GPEET expression may be linked to the activity levels of TAO.   Later studies 150 
showed that the expression of TAO influences the expression of GPEET, where a 151 
downregulation of both proteins may be important in the adaptation of the parasite to 152 
survive within the tsetse fly midgut (Walker et al. 2005).  153 
 154 
Structure  155 
Several structures of the alternative oxidase were proposed (Andersson & Nordlund 156 
1999; Berthold et al. 2000) prior to the publication of the crystal structure.  Initially, 157 
hydropathy plots suggested the alternative oxidases contain two conserved 158 
transmembrane regions, however later studies by Andersson and Nordlund 159 
(Andersson & Nordlund 1999) suggested alternative oxidases are not 160 
transmembrane proteins, but rather interfacial inner membrane proteins.  This was 161 
confirmed with the solving of the crystal structure of TAO (Shiba et al. 2013) which is 162 
devoid of any transmembrane domains, and instead has a hydrophobic face to 163 
partially bury the protein into the membrane  (Figure 3).  The recent publication of 164 
the crystal structure (Shiba et al. 2013) should help in the design of improved TAO 165 
inhibitors.  Sequence analysis of T. b. brucei, T. b. gambiense and T. b. rhodesiense 166 
showed that the amino acid sequence of TAO is identical in all three species, and 167 
therefore studies on TAO inhibitors and its co-structures can be directly applied from 168 
the common laboratory model T. b. brucei to the human disease-causing subspecies 169 
(Nakamura et al. 2010). 170 
Early studies on plant alternative oxidases revealed that they were inhibited by metal 171 
chelators (Schonbaum et al. 1971), and subsequent investigations using electron 172 
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paramagnetic resonance (EPR) (Berthold et al. 2002; Moore et al. 2008) and 173 
inductively coupled plasma-mass spectrometry (ICP-MS) (Kido et al. 2010) showed 174 
that the alternative oxidases contained a non-heme diiron catalytic core that was 175 
essential for catalytic activity and released during enzyme inactivation.  In the crystal 176 
structure in its oxidized state, the two Fe (III) ions are coordinated in a distorted 177 
square pyramidal geometry to four glutamate residues and a hydroxo-bridge (Figure 178 
4).  Two conserved histidines located nearby are also likely to be involved in Fe-179 
coordination in the reduced state, as determined through Fourier transform infrared 180 
spectroscopy (FTIR) investigations (Marechal et al. 2009).  Together, the two 181 
histidines and two glutamates form part of the two ExxH iron-binding motifs which 182 
are common to all AOX proteins and are required for activity (Chaudhuri et al. 1998; 183 
Ajayi et al. 2002).  184 
 185 
Mechanism of Catalysis 186 
The structure of TAO in complex with ubiquinol has not yet been solved so 187 
hypotheses regarding ubiquinol-binding have been made based upon the structure 188 
of TAO complexed with ascofuranone analog AF2779OH.  Superposition of ubiquinol 189 
over AF2779OH indicates that during catalysis a ubiquinol molecule is highly likely to 190 
occupy the same position.   The molecules gain entry to the diiron active site through 191 
a relatively short (~10 Å) hydrophobic channel from the membrane-bound side of 192 
TAO (Figure 4).   In this position the aromatic head of ubiquinol is less then 4.4 Å 193 
from the diiron core and is capable of forming hydrogen bonds with Arg118, Cys119 194 
and Tyr220, all of which may be involved directly in catalysis rather than purely 195 
substrate binding.  196 
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A mechanism of catalytic activity has been proposed (Moore et al. 2013 and Figure 197 
5), which begins with the diiron core in a reduced state (i.e. as Fe(II/II) bridged by a 198 
hydroxide).  Upon binding of molecular oxygen to the Fe(II/II) diiron core (Figure 5A), 199 
one iron passes an electron to an oxygen atom, forming a superoxo intermediate 200 
comprising an oxygen radical joined to an Fe(II/III) core.  The oxygen radical 201 
immediately abstracts a hydrogen atom (proton plus electron) from ubiquinol, 202 
yielding a ubisemiquinone and a hydroperoxo intermediate (Figure 5B). The unstable 203 
intermediate then undergoes a rearrangement whereby the hydroperoxo loses its 204 
proton and electron to the hydroperoxide bridge, which is then released as water 205 
(Figure 5C).  The Fe(II/III) core then gains an interaction with one of the histidines as 206 
determined in FTIR experiments (Marechal et al. 2009) and the second atom of the 207 
dioxygen forming a peroxodiiron.  Homolytic cleavage of the O-O bond (Figure 5D) 208 
yields an oxodiiron core, and one of the oxygens abstracts a hydrogen atom (proton 209 
plus electron) from Tyr220 generating a tyrosyl radical, as observed by Marechal et 210 
al (Marechal et al. 2009).  The tyrosyl can then pick up an electron and proton from 211 
the ubisemiquinone, either directly or via Cys119, releasing ubiquinone and returning 212 
Tyr220 to its resting state.   Moore’s model suggests that ubiquinol in a second 213 
channel can then provide two electrons and protons to release a second water and 214 
reduce the diiron core back to its original Fe(II/II) state bridged by a hydroxide ion 215 
through an unknown mechanism (Figure 5E).  However, the second ubiquinol 216 
channel may not be needed as the release of ubiquinone creates the space for the 217 
binding of a second ubiquinol in the same channel in a ping-pong binding fashion.  218 
Furthermore, the mechanism of electron and proton transfer could proceed through a 219 
similar route as for the first ubiquinol. 220 
 221 
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INHIBITORS OF THE TRYPANOSOME ALTERNATIVE OXIDASE 222 
The effectiveness of TAO inhibition to kill T. brucei has been well debated, with 223 
conflicting historical reports in the literature as to whether the inhibition of the GPO 224 
system alone is sufficient to kill the cells.  As shown in Figure 2, bloodstream form T. 225 
brucei rely solely on glycolysis for ATP production, as opposed to the ATP-producing 226 
oxidative phosphorylation used by procyclic forms. In the presence of TAO inhibitors 227 
the oxidation of Gly-3-P to DHAP is blocked, causing an accumulation of Gly-3-P in 228 
the glycosome, which is converted to glycerol by the ATP-producing glycerol kinase 229 
(Yabu et al. 2006).  This allows the recycling of glycosomal NAD+/NADH necessary 230 
to continue glycolysis anaerobically.  231 
Early reports of in vivo testing of TAO inhibitors suggested that although the 232 
compounds were able to inhibit the protein in vitro, this action alone was not 233 
sufficient to clear an infection when tested in animal models, due to anaerobic ATP 234 
production by the trypanosomes (Clarkson & Brohn 1976; Grady et al. 1993; Yabu et 235 
al. 1998).  It was believed that in order to cause cell death the anaerobic production 236 
of ATP also needed to inhibited with the co-administration of glycerol.  However, 237 
later investigations showed that bloodstream T. brucei exposed to TAO inhibitors 238 
alone are unable to survive for more than 24 hours using only anaerobic respiration 239 
(Helfert et al. 2001).  Furthermore, subsequent studies of a TAO inhibitor with an 240 
optimized dosing regimen but in the absence of glycerol, showed that TAO inhibition 241 
alone is sufficient to clear an infection in vivo (Yabu et al. 2003), indicating that 242 
inhibition of TAO is indeed a valid drug target. 243 
There are few compounds that have been shown to be inhibitors of TAO.  These 244 
compounds (Figure 6) all show structural similarity to the TAO substrate ubiquinol 245 
and are thought to act as competitive inhibitors, by binding to the ubiquinol binding 246 
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site. 247 
 248 
Salicylhydroxamic Acid 249 
The first compounds to be investigated as TAO inhibitors were the aromatic 250 
hydroxamates, such a salicylhydroxamic acid (SHAM) (Figure 6).  SHAM was known 251 
to be a potent inhibitor of the alternative oxidase in plants prior to the discovery of 252 
the GPO system in trypanosomes, hence the compound was investigated as a 253 
potential inhibitor of TAO.  It is thought that hydroxamic acids compete with ubiquinol 254 
for binding to TAO, and thus the compounds prevent the translocation of electrons 255 
from ubiquinol to oxygen (Pollakis et al. 1995).  SHAM was found to have moderate 256 
(EC50 = 15 M) activity against T. brucei in vitro and was shown to specifically inhibit 257 
all TAO activity at 1 mM (Opperdoes et al. 1976), although only a little effect was 258 
seen on ATP production.  However, when the trypanocidal effect of SHAM was 259 
investigated in vivo, the compound was unable to clear an infection and was only 260 
shown to be trypanocidal when co-administered with glycerol (Clarkson & Brohn 261 
1976).   262 
SHAM is a poor clinical candidate, due to its low solubility in water (Nihei et al. 263 
2002), which impairs the compounds from crossing the blood brain barrier, a critical 264 
characteristic required for drugs to effectively treat HAT.  Numerous attempts were 265 
made to improve the potency of hydroxamic acids against TAO, but were unable to 266 
match the potency of SHAM when tested in vivo (Grady et al. 1993).  Recently this 267 
issue has been revisited, Ott et al (Ott et al. 2006) developed novel SHAM analogs 268 
to improve its potency and solubility.  SHAM analogs such as ACD16 (Figure 6) were 269 
designed to include a prenyl side chain, as found in the TAO substrate ubiquinol, and 270 
a carbohydrate group to improve solubility, whilst keeping the 2-hydroxybenzoic acid 271 
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found in SHAM which is essential for TAO inhibition.  These modifications lead to the 272 
development of three compounds with up to five-fold greater potency than SHAM 273 
against rTAO, however in vitro testing against T. b. brucei growth and respiration 274 
revealed none of the modified compounds were more potent than SHAM.  There 275 
have been no subsequent reports on SHAM as a TAO inhibitor, although recent 276 
reports on the efficacy of TAO inhibitors without glycerol (Yabu et al. 2003) may 277 
renew interest in attempts to improve upon this compound.   278 
 279 
3,4-Dihydroxybenzoic Acid 280 
3,4-dihydroxybenzoic acids (Figure 6) were synthesized and tested as alternative 281 
inhibitors of TAO, and displayed higher inhibitory activity than SHAM when tested in 282 
vitro, but this high potency was lost when the compounds were tested in vivo (Grady 283 
et al. 1993).  To improve the bioavailability of the compounds, a series of N-n-alkyl-284 
3,4-dihydroxybenzamides were synthesized to increase solubility and decrease 285 
hydrolysis by serum esterases (Grady et al. 1993).  Structure activity relationships of 286 
this series of compounds showed increasing potency and decreasing solubility as 287 
the length of the alkyl substituent increases.  From this, N-n-butyl-3,4-288 
dihydroxybenzamide progressed to in vivo studies, and was found to effectively cure 289 
mice, but only when administered in conjunction with high doses of glycerol (450 290 
mg/kg drug with 15 g/kg glycerol).  Similar to SHAM, the high amount of glycerol 291 
necessary for a trypanocidal effect of N-n-butyl-3,4-dihydroxybenzamide rendered 292 
the compound unfavourable as a clinical drug candidate, and no work has been 293 
undertaken to identify if an optimized dosing regimen might clear infection in vivo 294 
without glycerol. 295 
 296 
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Ascofuranone  297 
Ascofuranone (Figure 6), is a biologically active natural product isolated from the 298 
fungus Ascochyta viciae.  Minagawa et al first showed that ascofuranone is a potent 299 
inhibitor of mitochondrial respiration of T. b. brucei, specifically the glucose- and 300 
glycerol-3-phosphate-dependent respiration (Minagawa et al. 1997).  Despite its high 301 
potency against TAO, ascofuranone was initially found to only be trypanocidal in the 302 
presence of glycerol, similar to the other TAO inhibitors.  The minimum inhibitory 303 
concentration  of ascofuranone alone was 250 M, whereas in the presence of 4 mM 304 
glycerol potency was improved several thousand-fold to 30 nM (Minagawa et al. 305 
1997).  Initially in vivo testing using mouse models found that ascofuranone was only 306 
curative when co-administered with a large amount (3 g/kg) of glycerol (Yabu et al. 307 
1998).  Despite these less than favourable initial results, the dosage of ascofuranone 308 
was improved to once again render it a promising clinical drug candidate.  Yabu et al 309 
(Yabu et al. 2003) trialled the optimal dosage to cure T. b. brucei mice without 310 
glycerol and determined that 100 mg/kg intraperitoneally for 4 days and 400 mg/kg 311 
orally for 8 days completely cleared an infection, with a 50% lethal dose (LD50) of 312 
>1.2 g/kg over 8 days.  This study also provided evidence of the effects of 313 
ascofuranone treatment on TAO, finding that ascofuranone decreased TAO activity 314 
by 30% and increased the level of TAO expression within the cells (Yabu et al. 315 
2003).   316 
Ascofuranone was also shown to inhibit the TAO of T. vivax, which causes animal 317 
trypanosomiasis (Nagana) in cattle.  The T. vivax TAO has 76% identical amino acid 318 
residues to T. brucei TAO (Suzuki et al. 2004) and the recombinant protein was 319 
shown to be three-fold more sensitive to ascofuranone.  Subsequent in vivo testing 320 
of ascofuranone in T. vivax infected mice found that a single intramuscular dose of 321 
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50 mg/kg ascofuranone without glycerol was sufficient to clear an infection, which 322 
could be reduced still further to 6 mg/kg over 4 days whilst retaining 100% cure rate 323 
within 48 hours.  The high efficacy of ascofuranone against T. vivax may make this 324 
compound a suitable drug for use against animal trypanosomiasis.   325 
Kinetic analysis of ascofuranone inhibition of rTAO indicated a competitive 326 
mechanism of inhibition against ubiquinol (Nihei et al. 2003).  Recent studies of 327 
ascofuranone have revealed the mechanism of inhibition, interaction with TAO and 328 
the pharmacophore responsible for the inhibitory activity of ascofuranone (Saimoto 329 
et al. 2013).  The length of the linker chain between the aromatic ring and furanone 330 
ring was shown to be important for its inhibitory activity, where the potency of 331 
inhibitor with a propyl linker was a thousand-fold lower compared to nonyl and decyl 332 
linkers.  This is likely due to the interactions between the prenyl tail and membrane 333 
lipid bilayers, where hydrophobicity of the inhibitor is influenced by the length of the 334 
prenyl tail, which is important to access the membrane-associated TAO (Mogi et al. 335 
2009; Saimoto et al. 2013).  Attempts to improve the potency and selectivity of 336 
ascofuranone-like analogs have been reported, such as the prenylphenol LL-Z1272 337 
series by Mogi et al (Mogi et al. 2009) (Figure 6), although no results from in vivo 338 
testing have been reported to date.   339 
 340 
Aurachin D 341 
Recently the natural product Aurachin D (Figure 6), a ubiquinol oxidase inhibitor 342 
isolated from the bacterium Stigmatella aurantiaca strain Sg a15, was shown to have 343 
inhibitory activity against T. b. gambiense (Li et al. 2013).  Aurachin D is a mimic of 344 
ubiquinol, with a quinolone core and prenyl chain.  Li et al (Li et al. 2013) found that 345 
Aurachin D inhibited T. b. gambiense with an IC50 of 1 M, with a selectivity index 346 
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greater than 35.  Various analogs of Aurachin D were synthesized and tested for 347 
trypanocidal activity, but none were improved compared to the natural product and 348 
hence the compound has not been taken forward into animal models.      349 
 350 
CONCLUSIONS AND FUTURE PERSPECTIVES 351 
Although drugs against TAO have been studied for over 40 years, there are still no 352 
drug candidates approaching clinical trials.  The search for an effective TAO inhibitor 353 
has been hampered until recently by the difficulty in obtaining a crystal structure of 354 
the relatively unstable purified protein, and the historical conflicting reports on 355 
whether inhibition of TAO alone is sufficient to kill T. brucei in vivo.  However, recent 356 
evidence renews the idea of TAO as a valid drug target.   Although there are few 357 
inhibitors of TAO reported in the literature, it is hoped that the publication of the 358 
crystal structure of TAO will significantly improve the design of novel, potent 359 
inhibitors against the enzyme.  Further work is also still required to confirm the 360 
mechanism of electron transfer by TAO and that ubiquinol is the true native co-361 
factor.   362 
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